Evidence map›Paper›PMID 42323780›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence.

Takeshi Murata, Hiraku Kumamaru, Masayuki Yoshida, Naoko Kinukawa, Shin Takayama, Akihiko Suto, Hiromitsu Jinno, Takanori Ishida, Naoki Niikura, Shigehira Saji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takeshi MurataDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan. tamurata@ncc.go.jp.ORCID http://orcid.org/0000-0003-0942-7599
Hiraku KumamaruDepartment of Health Data Science, Yokohama City University Graduate School of Data Science, 22-2, Seto, Kanazawa-Ku, Yokohama, Kanagawa, Japan.
Masayuki YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan.
Naoko KinukawaDepartment of Health Data Science, Yokohama City University Graduate School of Data Science, 22-2, Seto, Kanazawa-Ku, Yokohama, Kanagawa, Japan.
Shin TakayamaDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan.
Akihiko SutoDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan.
Hiromitsu JinnoDepartment of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo, Japan.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoki NiikuraDepartment of Breast Oncology, Tokai University School of Medicine, 143, Shimokasuya, Isehara, Kanagawa, Japan.
Shigehira SajiDepartment of Medical Oncology, School of Medicine, Fukushima Medical University, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of progesterone receptor (PR) status on the prognosis of breast cancer after isolated locoregional recurrence (ILRR) remains unclear. This study assessed the prognostic impact of the PR status of ILRR tumors in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

methodsThe study utilized data from the Japanese National Clinical Database (2004-2015), including 1,625 patients with ER+/HER2- ILRR. All participants were patients aged between 20 and 75 years at diagnosis who underwent curative surgery for ER+/HER2- primary breast cancer. Patients were classified into three groups based on the PR status of primary (p) and recurrent (r) tumors. We compared the overall survival (OS) and breast cancer-specific survival (BCSS) among the three groups using the Kaplan-Meier method with the log-rank test. ER and PR were considered positive if immunohistochemistry staining was positive in > 1% of tumor cells. For the ER expression levels in ILRR tumors, 1-10% were considered as ER-low positive.

resultsPatients with PR- ILRR (pPR-/rPR- and pPR+/rPR-) had significantly worse OS and BCSS than those with PR+ ILRR (pPR+/rPR+). Factors associated with worse outcomes included lymph node metastasis, a shorter disease-free interval, ER-low positivity, and no surgery for ILRR tumor.

conclusionsThis study highlights PR-negativity in ER+/HER2- ILRR tumors as a poor prognostic factor after ILRR, independent of the PR status of the primary breast cancer, emphasizing the need for tailored treatment strategies.

Indexed as

Breast NeoplasmsNeoplasm Recurrence, LocalReceptors, ProgesteroneAdultAgedBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansJapanKaplan-Meier EstimateMiddle AgedPrognosisReceptors, EstrogenYoung AdultBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerBreast cancer-specific survivalIsolated locoregional recurrenceOverall survivalProgesterone receptor

Identifiers

PMID42323780
PMCPMC13522001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.